[ad_1]
<div _ngcontent-c14 = "" innerhtml = "
A group of scientists associated with GTX Medical, published new evidence.
The new results, published yesterday Nature and its sister journal Nature Neuroscience, show that using patterns of electrical stimulation. Unlike previous studies published in Nature Medicine and The New England Journal of Medicine, which used continuous electrical signals, not pulses, two of the men maintained the ability to walk even when the stimulation device was turned off.
The patients still need to maintain their balance. But the results in the future can be treated in the future.
"Gregoire Courtine, a researcher at the Swiss Federal Institute of Technology (EPFL) in Lausanne, Switzerland, and the chief medical officer of GTX," said Gregoire Courtine.
In a commentary in Nature Neuroscience, University of Washington Biophysicist Chet Moritz, "The Breakthrough in the Treatment of Paralysis" and "Exhorting its Readers" at the University of Washington. injury can rise from their wheelchairs and begin to walk again. "
Courtine's group at EPFL treated patients who had somewhat more sustained sensation than patients treated by U.S. groups last month. He credits a lot of the difference to the way he is configured to the pacemaker-like devices that are being used to stimulate the nerves, and in which technology exactly when and where to stimulate. Jocelyne Bloch of Lausanne University Hospital, Courtine's co-author and a co-founder of GTX, says that the strategy is moving forward. "We have to start earlier," she says.
Moving forward will require clinical trials that test the new technologies more rigorously. GTX Medical Raised $ 40.3 Million From Investors Including Partners, Gimv, and Capital INKEF in August 2016, according to Pitchbook. Courtine says that the company may want to raise costs in the United States.
">
A group of scientists associated with GTX Medical, published new evidence.
The new results, published yesterday Nature and its sister journal Nature Neuroscience, show that using patterns of electrical stimulation. Unlike previous studies published in Nature Medicine and The New England Journal of Medicine, which used continuous electrical signals, not pulses, two of the men maintained the ability to walk even when the stimulation device was turned off.
The patients still need to maintain their balance. But the results in the future can be treated in the future.
"Gregoire Courtine, a researcher at the Swiss Federal Institute of Technology (EPFL) in Lausanne, Switzerland, and the chief medical officer of GTX," said Gregoire Courtine.
In a commentary in Nature Neuroscience, University of Washington biophysicist Chet Moritz, "The Breakthrough in the Treatment of Paralysis and Exhorting His Readers"[i]magine a time when technology and rehabilitation have made it easier to get people back to work. "
Courtine's group at EPFL treated patients who had somewhat more sustained sensation than patients treated by U.S. groups last month. He credits a lot of the difference to the way he is configured to the pacemaker-like devices that are being used to stimulate the nerves, and in which technology exactly when and where to stimulate. Jocelyne Bloch of Lausanne University Hospital, Courtine's co-author and a co-founder of GTX, says that the strategy is moving forward. "We have to start earlier," she says.
Moving forward will require clinical trials that test the new technologies more rigorously. GTX Medical Raised $ 40.3 Million From Investors Including Partners, Gimv, and Capital INKEF in August 2016, according to Pitchbook. Courtine says that the company may want to raise costs in the United States.